1.Discovery of Eucalyptin C, derived from the fruits of Eucalyptus globulus Labill., as a novel selective PI3Kγ inhibitor for immunosuppressive treatment.
Xiao-Long HU ; Wei SHEN ; Rong WANG ; Huan LONG ; Quan WANG ; Jia-Hao FENG ; Thi-Anh PHAM ; Fei XIONG ; Wen-Cai YE ; Hao WANG
Chinese Journal of Natural Medicines (English Ed.) 2021;19(11):844-855
The fruits of Eucalyptus globulus Labill. are known to have a plenty of medicinal properties, such as anti-tumor, anti-inflammatory, and immunosuppressive activity. Our previous study found that the phloroglucinol-sesquiterpene adducts in the fruits of E. globulus were immunosuppressive active constituents, especially Eucalyptin C (EuC). Phosphoinositide 3-kinases-γ (PI3Kγ) plays a pivotal role in T cell mediated excessive immune responses. In this study, EuC was first discovered to be a novel selective PI3Kγ inhibitor with an IC
Animals
;
Eucalyptus
;
Flavonoids
;
Fruit
;
Mice
;
Molecular Docking Simulation
;
Phosphoinositide-3 Kinase Inhibitors
2.Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer.
Chinese Journal of Oncology 2022;44(7):673-692
Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays an important role in the development of breast cancer and are closely associated with the resistance to endocrine therapy in advanced breast cancer. Therefore, anti-cancer treatment targeting key molecules in this signaling pathway has become research hot-spot in recent years. Randomized clinical trials have demonstrated that PI3K/AKT/mTOR inhibitors bring significant clinical benefit to patients with advanced breast cancer, especially to those with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER) 2-negative advanced breast cancer. Alpelisib, a PI3K inhibitor, and everolimus, an mTOR inhibitor, have been approved by Food and Drug Administration. Based on their high efficacy and relatively good safety profile, expanded indication of everolimus in breast cancer have been approved by National Medical Products Administration. Alpelisib is expected to be approved in China in the near future. The members of the consensus expert panel reached this consensus to comprehensively define the role of PI3K/AKT/mTOR signaling pathway in breast cancer, efficacy and clinical applications of PI3K/AKT/mTOR inhibitors, management of adverse reactions, and PIK3CA mutation detection, in order to promote the understanding of PI3K/AKT/mTOR inhibitors for Chinese oncologists, improve clinical decision-making, and prolong the survival of target patient population.
Breast Neoplasms/metabolism*
;
Consensus
;
Everolimus/therapeutic use*
;
Female
;
Humans
;
MTOR Inhibitors
;
Phosphatidylinositol 3-Kinase/metabolism*
;
Phosphatidylinositol 3-Kinases/metabolism*
;
Phosphoinositide-3 Kinase Inhibitors
;
Proto-Oncogene Proteins c-akt/metabolism*
;
Sirolimus/therapeutic use*
;
TOR Serine-Threonine Kinases/metabolism*
3.PI3K/p110β-specific inhibitors in castration-resistant prostate cancer.
National Journal of Andrology 2017;23(3):195-199
Advanced prostate cancer, especially at the castration-resistant stage, remains incurable clinically and, therefore, urgently requires new therapeutics for the patients. PI3K is a family of critical cell signal transduction molecules and their over-activation is an important factor in cancer development and progression. It has been demonstrated that class IA PI3K p110 is drastically overexpressed in prostate cancer and involved in androgen receptor-mediated gene expression and castration-resistant progression and regarded as a potential therapeutic target for prostate cancer. Several p110-specific inhibitors have been reported recently and two of them, GSK2636771 and AZD8186, are being tested in clinical trials.
Aniline Compounds
;
therapeutic use
;
Chromones
;
therapeutic use
;
Humans
;
Imidazoles
;
therapeutic use
;
Male
;
Morpholines
;
therapeutic use
;
Neoplasm Proteins
;
antagonists & inhibitors
;
Phosphatidylinositol 3-Kinases
;
metabolism
;
Phosphoinositide-3 Kinase Inhibitors
;
Prostatic Neoplasms, Castration-Resistant
;
drug therapy
;
enzymology
;
Protein Kinase Inhibitors
;
therapeutic use